Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.56
-1.5%
$3.87
$7.96
$24.15
$12.91M0.6316,864 shs28,297 shs
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$0.22
-2.3%
$0.39
$0.20
$3.89
$7.11M1.071.00 million shs628,399 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.24
+7.2%
$0.25
$0.10
$1.37
$10.80M1.21.57 million shs71,585 shs
NSTGQ
NanoString Technologies
$0.07
$0.07
$0.04
$5.18
$3.45M0.199.78 million shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-1.54%-0.39%-12.03%-70.23%-85.34%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-2.31%-20.25%-43.79%-65.58%+22,369,900.00%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
+7.23%-3.92%-12.65%+47.09%-81.52%
NSTGQ
NanoString Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.2054 of 5 stars
0.03.00.00.00.60.00.6
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.379 of 5 stars
0.03.00.00.00.62.50.0
NSTGQ
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.00
N/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
NSTGQ
NanoString Technologies
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$50K142.24N/AN/A($2.32) per share-0.10
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$80K134.96N/AN/A($2.68) per share-0.09
NSTGQ
NanoString Technologies
$127.26M0.03N/AN/A$0.98 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%8/7/2025 (Estimated)
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A
NSTGQ
NanoString Technologies
-$159.54M-$3.53N/AN/A-102.44%N/A-53.79%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
NSTGQ
NanoString Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
NSTGQ
NanoString Technologies
N/A
2.73
2.02

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
NSTGQ
NanoString Technologies
76.77%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
6.70%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
NSTGQ
NanoString Technologies
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3831.79 million20.04 millionN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable
NSTGQ
NanoString Technologies
55048.12 million46.63 millionOptionable

Recent News About These Companies

NanoString Technologies, Inc. (NSTGQ)
Bruker to Acquire NanoString with $392.6M Winning Bid
NanoString Technologies Inc (NSTGQ)

New MarketBeat Followers Over Time

Media Sentiment Over Time

AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.56 -0.04 (-1.54%)
As of 06/26/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$0.22 -0.01 (-2.31%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$0.23 +0.01 (+3.26%)
As of 06/27/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.24 +0.02 (+7.23%)
As of 06/27/2025 03:13 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

NanoString Technologies NASDAQ:NSTGQ

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.